XIDX
EPMT
Market cap354mUSD
Nov 12, Last price
2,340.00IDR
Name
Enseval Putera Megatrading Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Enseval Putera Megatrading Tbk., together with its associated companies, plays a significant role in Indonesia's pharmaceutical sector, primarily through the distribution and supply of its products. The organization's business activities are structured into three principal categories: Pharmaceutical, Consumer Products, and a diversified "Others" segment. Beyond pharmaceuticals, the company is involved in the commerce of medical and laboratory instruments and associated supplies, operates healthcare clinics, provides dental and various other specialized equipment, and offers calibration services. Furthermore, its trading ventures extend to raw materials crucial for pharmaceutical production, consumable goods for hemodialysis treatment, and a range of food and beverage items. The firm also delivers comprehensive warehousing solutions, including climate-controlled environments like chiller, cool, and ambient rooms, in addition to container chiller options. Founded in 1973, the company was originally named PT Arya Gupta Cempaka, adopting its current designation, PT Enseval Putera Megatrading Tbk., in August 1993. Headquartered in East Jakarta, Indonesia, it functions as a subsidiary of PT Kalbe Farma Tbk.
Key people
President Commissioner · since 2015
President Director · since 2021
Stanley Handiono Angkasa
Director · since 2019
Handi Halim
Director · since 2019
Sugianto Sugianto
Corporate Secretary · since 2017
Sanadi Boenjamin
Commissioner · since 2014
Djonny Hartono Tjahyadi
Commissioner · since 2021
Rosalina Irawaty
Independent Commissioner · since 2021
Lucky Surjadi Slamet
Independent Commissioner · since 2021
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||